Articles published by Qlaris Bio, Inc.

Qlaris Bio Appoints Robert Warner to Board of Directors

Today 7:45 EST

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio Announces First Patient Dosed in Phase II Nightingale Clinical Trial in Normal Tension Glaucoma Patients

August 26, 2025

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congress

June 23, 2025

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma

June 11, 2025

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

February 05, 2025

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma

April 30, 2024

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

April 02, 2024

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio to Present at Glaucoma 360 New Horizons Forum

January 27, 2023

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101

May 18, 2022

From Qlaris Bio, Inc.

Via Business Wire

Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma

April 15, 2021

From Qlaris Bio, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.